(secondQuint)Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers.

 A single blind, randomised, 3-period, 3-sequence single-dose crossover study to determine the pharmacokinetic dose proportionality of Clonidine MBT 50 1/2g and Clonidine MBT 100 1/2g and comparative bioavailability of clonidine from the Reference drug, Catapres(R) 100 1/2g oral tablets following single dose administration in healthy male and female subjects.

 36 subjects will be randomised for 30 to complete the study.

 The study will comprise of 3 Treatment Periods (1, 2 and 3) and a post study follow up (7 - 12 days after the last dose).

 Study drug will be administered on the morning of Day 1.

 Pharmacokinetic (PK) blood samples will be collected for each of three treatment periods.

 Safety will be evaluated at specified times throughout the study.

 There will be at least 7 days between dose administrations.

.

 Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers@highlight

The purpose of this study is to determine the pharmacokinetic dose proportionality of 50 1/2g and 100 1/2g Clonidine and comparative bioavailability of clonidine with that from the Reference drug, Catapres(R) 100 1/2g oral tablets following single dose administration in healthy subjects.

